Cited by 123Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

Amyloid burden and metabolic function in early-onset Alzheimer’s disease: parietal lobe involvement.

Ossenkoppele, R., Zwan, M. D., Tolboom, N., van Assema, D. M. E., Adriaanse, S. F., Kloet, R. W., Boellaard, R., Windhorst, A. D. +5 more·2012·Brain

Abstract

Alzheimer's disease with early onset often presents with a distinct cognitive profile, potentially reflecting a different distribution of underlying neuropathology. The purpose of this study was to examine the relationships between age and both in vivo fibrillary amyloid deposition and glucose metabolism in patients with Alzheimer's disease. Dynamic [(11)C]Pittsburgh compound-B (90 min) and static [(18)F]fluorodeoxyglucose (15 min) scans were obtained in 100 patients with Alzheimer's disease and 20 healthy controls. Parametric non-displaceable binding potential images of [(11)C]Pittsburgh compound-B and standardized uptake value ratio images of [(18)F]fluorodeoxyglucose were generated using cerebellar grey matter as reference tissue. Nine [(11)C]Pittsburgh compound-B-negative patients were excluded. The remaining patients were categorized into younger (n=45, age: 56 ± 4 years) and older (n=46, age: 69 ± 5 years) groups, based on the median age (62 years) at time of diagnosis. Younger patients showed more severe impairment on visuo-spatial function, attention and executive function composite scores (P<0.05), while we found a trend towards poorer memory performance for older patients (P=0.11). Differences between groups were assessed using a general linear model with repeated measures (gender adjusted) with age as between subjects factor, region (frontal, temporal, parietal and occipital and posterior cingulate cortices) as within subjects factor and [(11)C]Pittsburgh compound-…

Integrity signals

Registry

Crossref · 10.1093/brain/aws113

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ossenkoppele, R., Zwan, M. D., Tolboom, N., van Assema, D. M. E., Adriaanse, S. F., Kloet, R. W., Boellaard, R., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., Scheltens, P., van der Flier, W. M., & van Berckel, B. N. M.
Affiliations
Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Venue
Brain
Published
2012-05-03
Volume
135
Issue
7
Pages
2115-2125
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2150480085
Cited by
123
References
2
Citations by year
2026: 6 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 9 · 2020: 6 · 2019: 8 · 2018: 4 · 2017: 20 · 2016: 12 · 2015: 16 · 2014: 8 · 2013: 10 · 2012: 2
FWCI
8.20
Type
journal article
Language
en
Open access
closed
Locations
  • Brain (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
  • American Health Assistance Foundation
  • Center for Translational Molecular Medicine (02N-101)
  • Internationale Stichting Alzheimer Onderzoek (05512)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
early-onset Alzheimer's disease, amyloid deposition, glucose hypometabolism, parietal lobe, Pittsburgh compound B, FDG-PET, non-displaceable binding potential, regional cerebral glucose metabolism, age at diagnosis, cognitive profile, brain atrophy, posterior cingulate cortex, frontal lobe, temporal lobe, occipital lobe
MeSH terms
Aged, Alzheimer Disease, Amyloid, Aniline Compounds, Apolipoproteins E, Brain Mapping, Carbon Radioisotopes, Cognition Disorders, Female, Genotype, Glucose, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neuropsychological Tests, Parietal Lobe, Thiazoles, Case-Control Studies, Age of Onset, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review